Shanghai Haohai Biological Technology released its semi-annual report: hyaluronic acid product revenue increased by over 50% year-on-year, while revenue from multiple product lines in ophthalmology decreased.
Regarding new products, Shanghai Haohai Biological Technology has successfully obtained approval for the world's first organic cross-linked hyaluronic acid product 'Haimei Yuebai' developed globally in July this year, while the Asia Vets cross-linked collagen product entered the registration and inspection stage in June. Due to the selected price decline in the quantity-based procurement of artificial crystalline lenses, sales revenue decreased year-on-year. As for the consumer market, it is showing signs of fatigue coupled with an increase in the number of competing products, resulting in a decline in revenue from corneal shaping lens business.
AH trends diverge, Hang Seng Index up 0.6%, CNOOC up 4%, national bond futures slightly rebound.
Rare earth permanent magnets concept stocks pull back, photovoltaic and lithography themes also weaken. Hong Kong's real estate, banks, and oil & gas stocks are strong, CNOOC up 4%, Agricultural Bank of China and China Merchants Bank rise more than 2%. After experiencing a sharp drop yesterday, national bond futures rebounded in early trading, with 10-year and 30-year national bond futures contracts rising nearly 0.1% in early trading.
Is the healthcare market recovering? Mindray Healthcare acquires control of Whitney Healthcare at 25% premium | Insight Research
In the new year, A was born, and the leading device company Mindray entered the cardiovascular field at a premium.
2023 Interim Report | The next city is hard to find. How should Jiu'an Healthcare, which has 3 billion dollars in cash, spend money?
Invest
NASH testing works on a pay-per-use basis, and Furui shares surged 19% | Insight Research
The next 10 billion dollar market - NASH
2023 Interim Report | When CT Is No Longer a “Amulet”: What is Lianying Healthcare's MR Growth Space
Also watch This Morning
2023 Interim Report | Aibo Medical is increasing optometry and evasion and wants to launch the GDR to hit overseas markets?
Lustful and honest
Jimin Healthcare opens up a corner of high-end healthcare for the rich
A corner of the rich high-end healthcare industry is being interpreted by Jimin Healthcare (603222.SH). On July 25, the financial report released by Jimin Medical showed that revenue for the first half of 2023 was 444 million yuan, an increase of 1.64% over the previous year, while the net profit for the same period was 39 million yuan, down 39.50% from the previous year. The key reason for this sharp decline in profits points to the slump in exports of syringes, one of Jimin Medical's core products. “Mainly due to the decline in the company's exports of safe syringes (needles). The number of safe syringes (needles) exported by the company during the reporting period decreased by 73.33% compared with the same period last year
Amoy Diagnostics Said It Signed Cooperation Agreement With AstraZeneca UK's Unit Kudos Pharmaceuticals On HRD Test Product
Amoy Diagnostics, AstraZeneca team up to develop companion diagnostics programs
Lepu Biology officially landed on the Hong Kong Stock Exchange to focus on the field of tumor treatment.
02157.HK is officially listed on the Hong Kong Stock Exchange at HK $7.13 per share. Weiwu Capital (managed by Vivo Capital LLC), the cornerstone investor attracted by Lepu Biology's IPO, is the top fund in the global biomedical field. Another cornerstone investor, King Star, actually controls Lin Xianghong as a senior investor in the venture capital circle and has a wealth of successful investment experience in the industry. As cornerstone investors, Weiwu Capital and Lin Xianghong show that they are optimistic about the future development of Lepu Biology. It is understood that Lepu Biology on January 19, 2018
Review of December 24: full momentum this week, release the volume of the main funds to attack 5 shares next week.
December 24 news, the three major indices opened low, and then Prev maintained a low consolidation, the gem index led two cities down. In terms of the plate, medicine-related plates collectively rose, Chinese medicine stocks led the rise, food processing, retail and other consumer stocks were active against the trend; lithium batteries, photovoltaic, energy storage and other new energy tracks fell across the board, of which the weight fell more than 9% in the Ningde era. The index continued to weaken in the afternoon, with the gem index falling 2.7% at one point. Cultivate diamond, NFT concept stocks pull up; automobile, rare earth, fluorine chemical industry, digital currency and other sectors in the doldrums. Overall, market sentiment cooled, individual stocks showed a general downward trend, the two markets
BRIEF-Andon Health Says Unit's Home Test Kit For Covid-19 Obtains U.S. FDA's EUA
Shanghai Haohai Biological Technology's Q3 Profit Drops 6.6% as R&D Expenses Rise
Jiangsu Hualan New Pharmaceutical to Raise $304 Million in Shenzhen IPO
Medical Device Maker Cofoe Medical Targets $577 Million in Shenzhen IPO
Press Release: Fidmi Medical Launches U.S. Sales of Novel Low-Profile PEG Device and Raises $2.2 Million
Jiangsu Hualan New Pharmaceutical Launches IPO in Shenzhen
Medical Device Maker Cofoe Medical Technology Launches Shenzhen IPO
Global Viscosupplementation System Market Report 2021: Growing Demand for Minimally Invasive Procedures